- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04063033
IV Iron in Acute Decompensated Heart Failure
Randomized Bilnded Controlled Trial Comparing The Effect of IV Sodium Ferric Gluconate Complex (FERRLECIT R) on Outcome Patients Admitted Due To Acute Decompansated Heart Failure With Iron Deficiency
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Heart Failure (HF) constitutes one of the biggest burdens on the public health system, with incidence of 20 per 1000 persons above the age of 65 and up to 80 per 1000 persons above 85 years of age. Acute decompensated heart failure (ADHF) is the most common cause of hospitalizations among patients above the age of 65. Even with the advances in the treatment and management of HF, the prognosis of these patients remains poor. HF results in impaired quality of life (QoL), repeated hospitalizations and poor life expectancy.
Iron deficiency (ID) is a common comorbidity in HF patients, and is associated with poor outcome, worsening of New York Heart Association (NYHA) Class, and re-hospitalizations. While the mechanisms and pathophysiology of ID in HF is not well understood, it is presumed to be a combination of impaired absorption, renal dysfunction, hemodilution and drugs that are used for the treatment of HF.
The advantages of (intra-venous) IV ferric carboxymaltose to patients with reduced ejection fraction (HFrEF) with stable chronic heart failure and functional ID has been shown to reduce the risk of hospitalizations up to 60%, improve symptoms, exercise tolerance, functional capacity and overall QoL . Accordingly, the latest 2016 ESC Guidelines recommended the treatment in patients with HfrEF with reduced ejection fraction (HFrEF) and ID (Class IIA,LOC A).
The two major, placebo-controlled studies, mentioned above (CONFIRM-AF and FAIR-AF) have demonstrated the positive outcomes after correction of ID in stable HF patients, with a well-tolerated IV substance. However, there is no data today concerning the role of IV iron repletion in patients with decompensated HF and preserved EF. Furthermore, previous studies excluded a substantial portion of the HFrEF population recently admitted with (acute decompensated heart failure) ADHF and diagnosed with ID.
The effect of treating iron deficiency on quality of life an functional status has already been studied and found useful with various types of intravenous iron in the chronic kidney disease and inflammatory bowel disease.
In this study we aim to examine the effect of IV iron (ferric gluconate) which is a more affordable IV Iron on patients admitted due to acute heart failure with minimal exclusion criterias.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel
- Rambam Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients admitted due to acute decompensated heart failure to internal medicine department H or cardiology department.
Must meet two of the following criteria :
- NT pro BNP > 300 pg/ml (>800 pg/ml in the presence of Atrial Fibrillation).
- Peripheral pitting edema,
- Jugular Venous Distention,
- pulmonary edema/congestion according to physical examination or Chest X-ray.
- IV furosemide treatment on admission to ER or internal ward/cardiology department.
- Hb level 8-14 mg/dl on admission.
- Iron stores: Ferritin <100 or Ferritin 100-300 and Transferrin saturation < 20%.
- No evidence of active bleeding.
- Patient provided informed consent.
Exclusion Criteria:
- Cardiogenic shock or any other condition requiring IV vasopressors.
- Previous allergy or anaphylaxis due to IV Iron.
- Active malignancy undergoing treatment.
- Status post major surgery involving substantial blood loss in the past 3 months.
- Indication for Blood transfusion.
- Infection indicating IV antibiotics.
- History of acquired iron overload; known haemochromatosis or first relatives with hemochromatosis; and allergic disorders (asthma, eczema, and anaphylactic reactions).
- hemolytic anemia.
- History of chronic liver disease and/or alanine transaminase (ALT) or aspartate transaminase (AST) >3 times the upper limit of the normal range; chronic lung disease; myelodysplastic disorder; and known HIV/AIDS disease.
- Recipient of immunosuppressive therapy or renal dialysis. History of erythropoietin, IV iron therapy, and blood transfusion in previous 30 days.
- Unstable angina pectoris, as judged by the investigator; severe uncorrected valvular disease or left ventricular outflow obstruction; obstructive cardiomyopathy; uncontrolled fast atrial fibrillation or flutter (heart rate >110 beats per minute [bpm]); uncontrolled symptomatic brady- or tachyarrhythmias.
- Musculoskeletal limitation that, in the judgement of the investigator, would impair cardiopulmonary exercise testing.
- Pregnant or breastfeeding.
- Inability to comprehend study protocol.
- Parallel participation in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IV Iron treatment
Patients will be administered IV Iron for 3-5 days.
125 mg per day.
|
IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
Other Names:
|
No Intervention: No IV Iron treatment
Patients will receive standard treatment for heart failure without IV Iron.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Capacity
Time Frame: 12 and 24 Weeks
|
The functional capacity will be evaluated by the 6 minute walk test at baseline,12 weeks and 24 weeks follow up.
|
12 and 24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in NYHA
Time Frame: 12 and 24 weeks
|
Change in NYHA from baseline to 12 and 24 weeks
|
12 and 24 weeks
|
All cause mortality
Time Frame: 1 Year
|
Incidence of all cause mortality up to 1 year followup
|
1 Year
|
Hospitalizations due to heart failure.
Time Frame: 1 year
|
Incidence of hospitalisations due to heart failure up to 1 year followup
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Erez Marcusohn, MD, Rambam Health Care Campus
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0290-19 RMB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
Clinical Trials on IV iron - Sodium Ferric Gluconate Complex
-
Rambam Health Care CampusRecruitingAortic Stenosis | Iron Deficiency Anemia Due to Blood LossIsrael
-
Watson PharmaceuticalsCompletedIron Deficiency AnemiaUnited States, Canada, Mexico, Bulgaria, India, Russian Federation, Croatia, Poland
-
University of Maryland, BaltimoreCompleted
-
Watson PharmaceuticalsCompletedAnemia, Iron-Deficiency | Kidney Failure, ChronicUnited States, Puerto Rico
-
Watson PharmaceuticalsCompletedAnemia, Iron-Deficiency | Kidney Failure, ChronicUnited States
-
Watson PharmaceuticalsCompleted
-
University of SaskatchewanNot yet recruitingAnaemia in Ovarian CarcinomaCanada
-
Watson PharmaceuticalsCompletedAnemiaUnited States, Poland, Mexico, Serbia, Russian Federation
-
SanofiTerminated
-
Soroka University Medical CenterUnknownRenal Failure Chronic Requiring HemodialysisIsrael